.png "Untitled-2(10)")
When
May 26, 2026
9.00 am & 5.00 pm CEST
Where
The Zoom link will be sent by email upon registration
Info
• How to approach assay selection in clinical trials
• Key regulatory considerations for qualification and validation
• How to design and evaluate qualification experiments
• Practical guidance for working with clinical samples and controls
FluoroSpot enables sensitive, multiplex analysis of antigen-specific T-cell and B-cell responses. But what does it take to qualify it for clinical use?
In this joint webinar, Mabtech and IQVIA Laboratories share practical insights from clinical trial settings.
We will cover key considerations for assay qualification and validation, and walk through how to design and evaluate FluoroSpot qualification experiments.
Practical aspects such as sample quality, peptide selection, assay controls, and workflow optimization will be highlighted to support reliable, high-quality results.
What you'll learn
• When FluoroSpot is the right choice for your study• How to approach assay selection in clinical trials
• Key regulatory considerations for qualification and validation
• How to design and evaluate qualification experiments
• Practical guidance for working with clinical samples and controls
Speakers
Renata Varnaitė, PhD holds a PhD in infectious disease immunology from the Karolinska Institutet where she used FluoroSpot assay to assess T cell and B cell immunity in patients. Renata joined Mabtech in 2023 as Field Application Specialist, and was appointed Director of Global Strategic Partnerships in 2026.
Aurélie Mazy holds a Master’s degree in Biomedical Sciences with a specialization in Immunopathology. As a Scientist and Team Lead of the Immunogenicity department at IQVIA Laboratories, she has over 6 years of experience running cell-based assays and hands-on expertise with ELISpot and FluoroSpot technologies.
Sofie Denies holds a Master’s degree in Statistics and a PhD in Immuno-Oncology. As a biostatistician at IQVIA Laboratories, she has over 8 years of experience supporting the qualification of cell-based assays and preclinical immunogenicity evaluations. She has also been an invited speaker at international conferences on the analysis of preclinical immunological assays.
